Catalyst Pharmaceuticals, Inc. (CPRX) financial statements (2021 and earlier)

Company profile

Business Address 355 ALHAMBRA CIRCLE
CORAL GABLES, FL 33134
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments140127115102957760
Cash and cash equivalents130117115102904523
Short-term investments1010  53237
Receivables6677111010
Inventory, net of allowances, customer advances and progress billings5522210
Inventory5522210
Prepaid expense3111211
Other undisclosed current assets5575331
Total current assets:1591431311171119172
Noncurrent Assets
Operating lease, right-of-use asset 00111 
Property, plant and equipment0000000
Long-term investments and receivables     55
Long-term investments     55
Deposits noncurrent assets0000000
Deferred income tax assets3331     
Other undisclosed noncurrent assets      1
Total noncurrent assets:333201166
TOTAL ASSETS:1921751311181129778
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23182018241814
Accounts payable4261443
Accrued liabilities19161416201411
Total current liabilities:23182018241814
Noncurrent Liabilities
Long-term debt and lease obligation   111 
Operating lease, liability   111 
Liabilities, other than long-term debt      1
Accounts payable and accrued liabilities      1
Total noncurrent liabilities:   1111
Total liabilities:23182018251915
Stockholders' equity
Stockholders' equity attributable to parent170157111100887863
Common stock0000000
Additional paid in capital223222220218216214213
Accumulated other comprehensive income (loss)0(0)(0)0000
Accumulated deficit(54)(65)(108)(118)(129)(137)(150)
Total stockholders' equity:170157111100887863
TOTAL LIABILITIES AND EQUITY:1921751311181129778

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues31293029303129
Cost of revenue
(Cost of Goods and Services Sold)
(5)(4)(4)(4)(4)(4)(4)
Gross profit:26252525262725
Operating expenses(18)(14)(15)(14)(18)(13)(18)
Other undisclosed operating income      4
Operating income:912101181411
Nonoperating income
(Other Nonoperating income)
0000000
Income from continuing operations before income taxes:912101181411
Income tax expense (benefit)332(1)(1)(0)(1)(0)
Net income available to common stockholders, diluted:1143101081411

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income:1143101081411
Other comprehensive income (loss)0(0)(0)0(0)(0)0
Comprehensive income, net of tax, attributable to parent:1143101181411

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: